Navigation Links
Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
Date:11/1/2010

MOUNTAIN VIEW, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report results for its fiscal quarter ended September 30, 2010, on Tuesday, November 9, 2010 following the close of the U.S. financial markets.  As the Company recently held an investor conference call on October 11th, there will not be a conference call held in conjunction with the release of the Company's third quarter results.  The Company will provide a regulatory update regarding its AZ-004 New Drug Application (NDA) after conducting a follow-on meeting with the U.S. Food and Drug Administration (FDA).

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted a New Drug Application in December 2009.  In October 2010, the Company received a Complete Response Letter (CRL) from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and anticipates meeting with the FDA before the end of the year to discuss the CRL.  For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% of its original ... to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out of ...
(Date:2/11/2016)... ROLLING MEADOWS , Ill. and INDIANAPOLIS ... major milestone for many young people, but for those ... demanding. Not only do these students juggle class schedules, ... challenges of living with type 1 diabetes. On top ... the first time. Diabetes Scholars Foundation ...
(Date:2/11/2016)... Feb. 11, 2016  AbbVie, a global biopharmaceutical ... Scholarship, designed to provide financial support for exceptional ... pursue higher education goals. Fifteen scholars will be ... school year. The AbbVie Rheumatology Scholarship is currently ... vice president, corporate social responsibility, brand and communications, ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... The president released ... Military Health System but would shift more of the cost burden to military beneficiaries. ... plan laid out in the defense budget as including limited quantifiable benefit fixes mixed ...
(Date:2/11/2016)... Texas (PRWEB) , ... February 11, 2016 , ... ... plastic surgery, dermatology and women’s health, is pleased to announce the promotions of ... Development Partners sales team, Steve Catone to executive vice president of North American ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... call for nominations seeking candidates for the Board of Commissioners. Individuals interested in ... skills and experience with diversity of clinical practice settings and across allied health ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... their ongoing community involvement program, introduces a new charity campaign to raise funds ... are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) ...
Breaking Medicine News(10 mins):